Media Spotlight
In an article in CURE, PC3I Faculty Emily Ko, MD, MSCR, discusses targeted therapy, a form of cancer treatment aimed at specific aspects of cancer cells which is an emerging treatment for endometrial cancer.
About 30% of patients with endometrial cancer have tumors that are MSI (microsatellite instability)-high, a characteristic linked to a high number of genetic mutations in cancerous cells. These abnormalities can be directly targeted with certain drugs.
“When we started to get down to the genomic levels of these tumors, we realized that just because some endometrial cancers may look [similar] under the microscope, they may still behave biologically different based on genomic signature,” says Ko. “Based on that genomic signature, there may be biologic pathways that we can target.”
Dr. Ko further discusses the potential of targeted therapies as an alternative treatment for endometrial cancer in the full article at CURE.
Related News
Media Spotlight
PC3I Associate Director Lola Fayanju on Breast Cancer Screening Recommendations
09.27.2023
In an interview with the Philadelphia Inquirer, PC3I Associate Director Lola Fayanju commented on recently updated breast cancer screening recommendations.
Media Spotlight
Proton Therapy Study at Penn Medicine Gains New Attention
02.14.2023
As part of the RadComp study, Penn Medicine and over 20 radiation centers nationwide are comparing the effectiveness of photon therapy and proton therapy to treat breast cancer.
Media Spotlight
Machine Learning-Triggered Behavioral Nudges Quadrupled Serious Illness Conversation Rates
01.12.2023
A team led by PC3I Innovation Faculty Ravi Parikh has found that machine learning-triggered behavioral nudges quadrupled the rates of seriousness illness conversations for patients with advance cancer.